Senores Pharmaceuticals Ltd (SENORES) Q3FY26 Concall Summary - Dec-2025 Qtr
Performance Overview
- The company delivered a strong, broad-based performance in Q3 FY26, driven by robust growth in both regulated and emerging markets, leading to the highest-ever quarterly revenue, EBITDA, and PAT in the emerging market business.
- A key strategic milestone was the completion of the acquisition of a 75% stake in Apna Pharma, a USFDA-approved facility, which is expected to enhance manufacturing capabilities, provide access to UK and Canadian markets, and add five approved ANDAs.
- The company demonstrated significant portfolio expansion, with its ANDA portfolio nearly quadrupling year-over-year from 12 to 46 approved ANDAs as of December 2025, providing a strong pipeline for future launches.
- Operational efficiency and disciplined working capital management led to a significant improvement in the EBITDA to operating cash flow conversion, underscoring a strong focus on cash flow generation.
- The India branded generics business continued its high-growth momentum, with revenues increasing more than six-fold on a year-over-year basis, contributing significantly to the consolidated performance.
Financial Metrics
Log in to Stocksigma to read the Financial Metrics section of this summary.
Operating Performance / Business Segments
Log in to Stocksigma to read the Operating Performance / Business Segments section of this summary.
Key Discussions & Insights
Log in to Stocksigma to read the Key Discussions & Insights section of this summary.
Outlook and Guidance
Log in to Stocksigma to read the Outlook and Guidance section of this summary.
Challenges / Concerns
Log in to Stocksigma to read the Challenges / Concerns section of this summary.
Industry / Competitive Landscape
Log in to Stocksigma to read the Industry / Competitive Landscape section of this summary.
Overall Summary
Log in to Stocksigma to read the Overall Summary section of this summary.